A Phase 2 interventional study of GWP42003-P 5 mg/kg/day Dose and Placebo control in Epilepsy and Dravet Syndrome, sponsored by Jazz Pharmaceuticals. Completed at 11 sites in 2 countries. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2022-09-28.
Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing cannabidiol in Epilepsies, Myoclonic — 1 open to participants now, 2 under way, none of them phase 3. Cannabidiol · Epilepsies, Myoclonic.
Among the 14 studies testing cannabidiol in Epilepsies, Myoclonic, this one is the 7th largest by enrollment, is one of 2 that started in 2014, is the only one in phase 2, and was the 1st registered.
92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.
Browse Epilepsies, Myoclonic studies →1 of the 14 studies testing cannabidiol in Epilepsies, Myoclonic is open now, in 1 country. Recruiting first, the newest first:
Elizabeth Donner · Sites in Canada
Ages 2–18
By country, each count listing its studies:
Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.
This study: 4 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 8 · Phase 4 2
First in 2014; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is close to the median of 31 across 56 interventional studies indexed under Epilepsies, Myoclonic.
Median enrollment 30 across the 14 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 8 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 8 studies filed under Epilepsies, Myoclonic — fewer than ten, so there is no comparison to draw.
1 of the studies testing cannabidiol in Epilepsies, Myoclonic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05044819Jazz PharmaceuticalsAssessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing cannabidiol in Epilepsies, Myoclonic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and pharmacokinetics (PK) of multiple doses of GWP42003-P compared with placebo in children with Dravet syndrome.
This multi-center study consisted of 2 parts: Part A and Part B. Only Part A is described in this record. Part A was a randomized, double-blind 21-day treatment study period. Participants were randomized to one of 3 doses of active drug or placebo at a 4:1 ratio.
Participants who satisfied all inclusion and none of the exclusion criteria were assigned a unique participant number and then began a 28-day baseline observation period.
Eligible participants were then randomly assigned to receive one of 3 dose levels of GWP42003-P: 5 milligrams (mg) per kilogram (kg) per day, 10 mg/kg/day, 20 mg/kg/day, or matching placebo.
There were three groups of ten participants. In each group, participants were randomly assigned so that eight participants received active treatment and two participants received placebo. Participants received GWP42003-P or placebo for a 21-day exposure period, which consisted of a titration period, followed by a stable dose period.
A PK assessment took place after the first single dose of GWP42003-P. There was a second PK assessment after 21 days of consecutive dosing with GWP42003-P. Participants who took clobazam (CLB) as an adjunctive treatment were asked to take their usual dose 2 hours prior to attending the clinic. The same recommendation was made for other concomitant antiepileptic drugs (AEDs), if applicable. This was so that the pre-treatment (with GWP42003-P) plasma concentrations of CLB, its major metabolite N-desmethylclobazam, and any other concomitant AEDs could be measured, and the impact of GWP42003-P treatment on these levels evaluated. Interim clinic visits to (primarily) evaluate safety and adherence to the titration regimen took place at 7 and 14 days of treatment.
After 21 days of treatment, all participants commenced a 10-day down-titration taper period. An independent Data Safety Monitoring Committee reviewed unblinded safety and PK data and recommended the target dose (up to 20 mg/kg/day) for Part B of the study and for an open label extension study. Once the safety review of Part A data had taken place, participants had the option of entering the open label extension study.
A follow-up telephone call was made 28 days after the end of dosing for participants who did not enter the open label extension study within this time-frame.
Throughout the 21-day treatment period and the 10-day taper period, there were regular safety telephone calls (approximately every 2 days) to check participant status. Weekly safety telephone calls were made during the 28-day follow-up period.
92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.
This study's enrollment of 34 is close to the median of 31 across 56 interventional studies indexed under Epilepsies, Myoclonic.
Browse Epilepsies, Myoclonic studies →Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Compared within Epilepsies, Myoclonic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received GWP42003-P 5 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 5 mg/kg/day over 3 days and remained at this dose for the rest of the 21-day treatment period (19 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
Drug: GWP42003-P 5 mg/kg/day Dose
Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the rest of the 21-day treatment period (15 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
Drug: GWP42003-P 10 mg/kg/day Dose
Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the rest of the 21-day treatment period (11 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
Drug: GWP42003-P 20 mg/kg/day Dose
Participants received placebo (0 mg/mL CBD), volume matched to one of the 3 dose levels (5, 10, or 20 mg/kg/day), administered orally, half in the morning and half in the evening for 21 days. To maintain the blinded aspect of the study, participants titrated the placebo dose over 3 to 11 days according to the matched investigational medicinal product (IMP) group (3, 7, and 11 days for the 5, 10, or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the rest of the 21-day treatment period. The 21-day treatment period was followed by a 10-day taper (10% per day of the matched dose) period.
Drug: Placebo control
Drug page: Cannabidiol
GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
Also known as: Cannabidiol, Epidiolex
Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Also known as: Placebo
Drug page: Cannabidiol
GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
Also known as: Cannabidiol, Epidiolex
Drug page: Cannabidiol
GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
Also known as: Cannabidiol, Epidiolex
Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)
A TEAE was defined as an adverse event (AE) with an onset date on or after the first dose of IMP. If an AE had a partial onset date and it was unclear from the partial date (or the stop date) whether the AE started prior to or following the first dose of IMP then the AE was considered a TEAE. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through the Safety Follow-up Visit (Day 60) is presented. A summary of serious and all other non-serious AEs regardless of causality is located in the Adverse Events module.
Time frame: Baseline (Day 1) through Safety follow-up visit (Day 60)
Area Under The Concentration-Time Curve Calculated To The Last Observable Concentration At Time T (AUC0-t) For CBD And Its Metabolites At Days 1 And 22
AUC0-t for CBD and its major metabolites, 6-hydroxy-CBD (6-OH-CBD), 7-hydroxy-CBD (7-OH-CBD), and 7-carboxy-CBD (7-COOH-CBD) were calculated using blood samples collected before and after IMP dosing on Days 1 and 22. One sample was collected predose, 2 to 3 hours postdose, and 4 to 6 hours postdose for CBD and its metabolites. Results are presented for participants who received GWP42003-P at 5, 10, or 20 mg/kg/day during the study and for participants with a numeric result for the given evaluation.
Time frame: Predose and 2-6 hours postdose on Days 1 and 22
Mean Percentage Change From Baseline To End Of Treatment In Plasma Clobazam (CLB) And N-Desmethylclobazam (N-CLB) Concentrations
Plasma concentrations of CLB and N-CLB were measured on Days 1 and 22. Participants were instructed to take their daily dose of CLB 2 hours prior to the anticipated pre-IMP blood specimen collection on both days. Blood samples were collected prior to administration of IMP. Results are presented for a subgroup of participants who took CLB during the study and had PK samples analyzed at both PK sampling visits (Days 1 and 22).
Time frame: Predose on Days 1 and 22
| Milestone | GWP42003-P 5 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|---|---|
| Started | 10 | 8 | 9 | 7 |
| Safety analysis set | 10 | 8 | 9 | 7 |
| Completed | 10 | 7 | 8 | 7 |
| Not completed | 0 | 1 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 0 | 0 | 1 | 0 |
| Milestone | GWP42003-P 5 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|---|---|
| Started | 10 | 7 | 8 | 7 |
| Completed | 9 | 7 | 8 | 5 |
| Not completed | 1 | 0 | 0 | 2 |
| Withdrew: Participant refused study drug | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
A TEAE was defined as an adverse event (AE) with an onset date on or after the first dose of IMP. If an AE had a partial onset date and it was unclear from the partial date (or the stop date) whether the AE started prior to or following the first dose of IMP then the AE was considered a TEAE. The number of participants who experienced one or more severe TEAEs after dosing on Day 1 through the Safety Follow-up Visit (Day 60) is presented. A summary of serious and all other non-serious AEs regardless of causality is located in the Adverse Events module.
| Participants | GWP42003-P 5 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|---|---|
| Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs) | 2 | 1 | 0 | 1 |
AUC0-t for CBD and its major metabolites, 6-hydroxy-CBD (6-OH-CBD), 7-hydroxy-CBD (7-OH-CBD), and 7-carboxy-CBD (7-COOH-CBD) were calculated using blood samples collected before and after IMP dosing on Days 1 and 22. One sample was collected predose, 2 to 3 hours postdose, and 4 to 6 hours postdose for CBD and its metabolites. Results are presented for participants who received GWP42003-P at 5, 10, or 20 mg/kg/day during the study and for participants with a numeric result for the given evaluation.
| hours * nanograms/mL | GWP42003-P 5 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | GWP42003-P 20 mg/kg/Day Dose |
|---|---|---|---|
| Day 1 CBD | 70.61 ± 20.38 | 66.35 ± 120.8 | 73.69 ± 96.64 |
| Day 22 CBD | 240.8 ± 100.8 | 721.8 ± 79.92 | 962.6 ± 93.43 |
| Day 1 6-OH-CBD | 3.27 ± 132 | 2.79 ± 87.7 | 5.16 ± 57.2 |
| Day 22 6-OH-CBD | 9.33 ± 119 | 26.3 ± 82.9 | 58.6 ± 90.1 |
| Day 1 7-OH-CBD | 21.9 ± 57.0 | 18.4 ± 299 | 30.2 ± 105 |
| Day 22 7-OH-CBD | 131 ± 107 | 244 ± 120 | 508 ± 96.0 |
| Day 1 7-COOH-CBD | 297 ± 97.3 | 125 ± 1750 | 195 ± 573 |
| Day 22 7-COOH-CBD | 4190 ± 81.20 | 9220 ± 178 | 15500 ± 148 |
Plasma concentrations of CLB and N-CLB were measured on Days 1 and 22. Participants were instructed to take their daily dose of CLB 2 hours prior to the anticipated pre-IMP blood specimen collection on both days. Blood samples were collected prior to administration of IMP. Results are presented for a subgroup of participants who took CLB during the study and had PK samples analyzed at both PK sampling visits (Days 1 and 22).
| percent change | GWP42003-P 5 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|---|---|
| % change in CLB | -1.2 | 18.0 | 29.6 | 15.1 |
| % change in N-CLB | 258.7 | 170.7 | 228.9 | -5.6 |
Collected over Up to Day 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GWP42003-P 5 mg/kg/Day Dose | — | 1/10 (10%) | 8/10 (80%) |
| GWP42003-P 10 mg/kg/Day Dose | — | 2/8 (25%) | 5/8 (62.5%) |
| GWP42003-P 20 mg/kg/Day Dose | — | 1/9 (11.1%) | 7/9 (77.8%) |
| Placebo | — | 1/7 (14.3%) | 6/7 (85.7%) |
| Event | GWP42003-P 5 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/10 | 2/8 | 0/9 | 0/7 |
| Viral InfectionInfections and infestations | 0/10 | 0/8 | 0/9 | 1/7 |
| ConvulsionNervous system disorders | 0/10 | 1/8 | 0/9 | 1/7 |
| Rash Maculo-papularSkin and subcutaneous tissue disorders | 0/10 | 1/8 | 0/9 | 0/7 |
| Parvovirus InfectionInfections and infestations | 0/10 | 0/8 | 1/9 | 0/7 |
| Status EpilepticusNervous system disorders | 1/10 | 0/8 | 0/9 | 0/7 |
| Event | GWP42003-P 5 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 0/10 | 1/8 | 4/9 | 0/7 |
| SomnolenceNervous system disorders | 2/10 | 3/8 | 0/9 | 1/7 |
| PyrexiaGeneral disorders | 3/10 | 1/8 | 0/9 | 0/7 |
| Abnormal behaviourPsychiatric disorders | 3/10 | 0/8 | 0/9 | 0/7 |
| FatigueGeneral disorders | 0/10 | 0/8 | 1/9 | 2/7 |
| GastroenteritisInfections and infestations | 1/10 | 0/8 | 0/9 | 2/7 |
| Abdominal Pain UpperGastrointestinal disorders | 0/10 | 0/8 | 2/9 | 0/7 |
| SedationNervous system disorders | 2/10 | 0/8 | 2/9 | 0/7 |
| AtaxiaNervous system disorders | 2/10 | 0/8 | 1/9 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 0/8 | 0/9 | 1/7 |
Safety Analysis Set: included all participants randomized to treatment who received at least 1 dose of IMP. Participants were analyzed according to the treatment they received. Only participants for whom it had been confirmed that they did not take any IMP were excluded from the safety analysis set.
| Age, Continuous(Years) | GWP42003-P 5 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | GWP42003-P 20 mg/kg/Day Dose | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 7.150 ± 1.8955 | 7.368 ± 2.1229 | 8.671 ± 1.7957 | 6.978 ± 0.9476 | 7.568 ± 1.8300 |
| Sex: Female, Male(Participants) | GWP42003-P 5 mg/kg/Day Dose | GWP42003-P 10 mg/kg/Day Dose | GWP42003-P 20 mg/kg/Day Dose | Placebo | Total |
|---|---|---|---|---|---|
| Female | 5 | 5 | 6 | 2 | 18 |
| Male | 5 | 3 | 3 | 5 | 16 |
Ran from Oct 2014 to primary completion in Mar 2015, 4 months.
Results were first posted in Jul 2018, 3 years 4 months after primary completion. A results delay was requested in Jun 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol